- Home
- ENTO vs VERO Comparison
ENTO vs VERO Comparison
Compare ENTO & VERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTO
- VERO
- Stock Information
- Founded
- ENTO 2014
- VERO N/A
- Country
- ENTO United States
- VERO Canada
- Employees
- ENTO N/A
- VERO N/A
- Industry
- ENTO Biotechnology: Pharmaceutical Preparations
- VERO Medical/Dental Instruments
- Sector
- ENTO Health Care
- VERO Health Care
- Exchange
- ENTO Nasdaq
- VERO Nasdaq
- Market Cap
- ENTO 2.9M
- VERO 2.4M
- IPO Year
- ENTO 2016
- VERO N/A
- Fundamental
- Price
- ENTO $0.49
- VERO $0.31
- Analyst Decision
- ENTO
- VERO
- Analyst Count
- ENTO 0
- VERO 0
- Target Price
- ENTO N/A
- VERO N/A
- AVG Volume (30 Days)
- ENTO 68.7K
- VERO 128.1K
- Earning Date
- ENTO 11-13-2024
- VERO 03-31-2025
- Dividend Yield
- ENTO N/A
- VERO N/A
- EPS Growth
- ENTO N/A
- VERO N/A
- EPS
- ENTO N/A
- VERO N/A
- Revenue
- ENTO N/A
- VERO $67,200,000.00
- Revenue This Year
- ENTO N/A
- VERO N/A
- Revenue Next Year
- ENTO N/A
- VERO $4.95
- P/E Ratio
- ENTO N/A
- VERO N/A
- Revenue Growth
- ENTO N/A
- VERO N/A
- 52 Week Low
- ENTO $0.19
- VERO $0.28
- 52 Week High
- ENTO $9.35
- VERO $1.59
- Technical
- Relative Strength Index (RSI)
- ENTO 43.83
- VERO 38.70
- Support Level
- ENTO $0.45
- VERO $0.30
- Resistance Level
- ENTO $0.54
- VERO $0.32
- Average True Range (ATR)
- ENTO 0.06
- VERO 0.02
- MACD
- ENTO 0.00
- VERO -0.00
- Stochastic Oscillator
- ENTO 24.31
- VERO 12.62
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.